Cerebrospinal fluid HIV RNA and drug levels with combination ritonavir and saquinavir

Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology

Volumn 21, Issue 5, 1999, Pages 371-375

  Kravcik, Stephen ^a   Gallicano, Keith ^a,b   Roth, Virginia ^a   Cassol, Sharon ^b   Hawley Foss, Nanci ^a   Badley, Andrew ^a   Cameron, D William ^a  

^a UNIVERSITY OF OTTAWA   (Canada)

^b OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

Author keywords

Brain; Cerebrospinal fluid; Neurologic; Ritonavir; Saquinavir

Indexed keywords

PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR;

ADULT; ANTIVIRAL ACTIVITY; ARTICLE; BLOOD BRAIN BARRIER; CENTRAL NERVOUS SYSTEM INFECTION; CEREBROSPINAL FLUID ANALYSIS; CONTROLLED STUDY; DRUG BLOOD LEVEL; ENZYME INHIBITION; HUMAN; HUMAN EXPERIMENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; PRIORITY JOURNAL; VIREMIA;

EID: 0032839781     PISSN: 10779450     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042560-199908150-00003     Document Type: Article

References (22)

1. Cameron DW, Japour AJ, Xu Y, et al. Ritonavir and saquinavir combination therapy for the treatment of HIV infection. AIDS 1998;13:213-24.
2. Angel JB, Kumar A, Parato K, et al. Improvement in cell-mediated immune function during potent anti-human immunodeficiency virus therapy with ritonavir plus saquinavir. J Infect Dis 1998;177: 898-904.
3. Rolinski B, Bogner JR, Sadri I, Wintergerst U, Goebel FD. Absorption and elimination kinetics of zidovudine in the cerebrospinal fluid in HIV-1-infected patients. J Acquir Immune Defic Syndr Human Retrovirol 1997;15:192-7.
4. Foudraine N, de Wolf F, Hoetelmans R, Portegies P, Maas J, Lange J. CSF and serum HIV-RNA levels during AZT/3TC and d4T/3TC treatment [abstract LBS]. Presented at the 4th Annual Conference on Retroviruses and Opportunistic Infections, Washington, DC, 1997.
5. Silverstein H, Riska P, Johnstone JN, et al. Nevirapine, a non-nucleoside reverse transcriptase inhibitor, freely enters the brain and crosses the placental barrier [abstract Tu.B.2325]. Presented at the XI International Conference on AIDS, Vancouver, British Columbia, Canada, 1996.
6. Schmitt FA, Bigley JW, McKinnis R, et al. Neuropsychological outcome of zidovudine in the treatment of patients with AIDS and AIDS-related complex. N Engt J Med 1987;319:1573-8.
7. Sidtis JJ, Gatsonis C, Price RW, et al. Zidovudine treatment of the AIDS dementia complex: results of a placebo-controlled trial. Ann Neural 1993;33:343-9.
8. Burger DM, Kraageveld CL, Meenhorst PL, et al. Study on didanosine concentrations in cerebrospinal fluid. Pharm World Sci 1995;17:218-21.
9. Wolters P, Brouwers P, Moss H, et al. The effect of dideoxyinosine (DDI) on the cognitive functioning of children with HIV infection after 6 and 12 months of treatment [abstract W.B.2051]. Presented at the 7th International Conference on AIDS, Florence, Italy, 1991.
10. Baker CJ, Englund J, Raskino C, McKinney R, Fowler M. Comparison of zidovudine (ZDV), didanosine (DDI), or combination ZDV/DDI therapy in symptomatic, HIV-infected children (ACTG 152) [abstract Th.B.940]. Presented at the XI International Conference on AIDS, Vancouver, British Columbia, Canada, 1996.
11. Enting RH, Hoetelmans RMW, Lange JMA, Burger DM, Beijnen JH, Portegies P. Antiretroviral drugs and the central nervous system [review]. AIDS 1998;12:1941-55.
12. Zhu T, Wang N, Carr A, et al. Genetic characterization of human immunodeficiency virus type 1 in blood and genital secretions: evidence for viral compartmentalization and selection during sexual transmission. J Virol 1996;70:3098-3107.
13. Kroodsma KL, Kozal MJ, Hamed KA, Winters MA, Merigan TC. Detection of drug resistance mutations in the human immunodeficiency virus type l (HIV-1) pol gene: differences in semen and blood HIV-1 RNA and proviral DNA. J Infect Dis 1994;170: 1292-5.
14. Marsh KC, Eiden E, McDonald E. Determination of ritonavir, a new HIV protease inhibitor, in biological samples using reversed-phase high-performance liquid chromatography. J Chromatogr Biomed Sci Appl 1997;704:307-13.
15. Cassol S, Weniger BG, Babu PG, et al. Detection of HIV-1 env subtypes A, B, C and E in Asia using dried blood spots: a new surveillance tool for molecular epidemiology. AIDS Res Hum Retroviruses 1996;12:1435-41.
16. Conrad AJ, Schmid P, Syndulko K, et al. Quantifying HIV-1 RNA using the polymerase chain reaction on cerebrospinal fluid and serum of seropositive individuals with and without neurological abnormalities. J Acquir Immune Defic Syndr Hum Retrovirol 1995; 10:425-35.
17. Kakuda TN, Struble KA, Piscitelli SC. Protease inhibitors for the treatment of human immunodeficiency virus infection. Am J Health-Syst Pharm 1998;55:233-54.
18. Molla A, Vasavanonda S, Kumar G, et al. Human serum attenuates the activity of protease inhibitors toward wild-type and mutant human immunodeficiency virus. Virology 1998;250:255-62.
19. Rolinski B, Bogner JR, Sadri I, Wintergerst U, Goebel FD. Absorption and elimination kinetics of zidovudine in the cerebrospinal fluid in HIV-1-infected patients. J Acquir Immune Defic Syndr Hum Retrovirol 1997;15:192-7.
20. Kim RB, Fromm MF, Wandel C, et al. The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. J Clin Invest 1998;101:289-94.
21. Schinkel AH, Wagenaar E, Mol CA, van Deemter L. P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. J Clin Invest 1996;97:2517-24.
22. Gisolf EH, Portegies P, Hoetelmans R, et al. Effect of ritonavir (RTV)/saquinavir (SQV) versus RTV/SQV/stavudine (d4T) on cerebrospinal fluid (CSF) HIV-RNA levels: preliminary results [Abstract 32197]. Presented at the XII World AIDS Conference, Geneva, 1998.